Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Patrick Yung Chih Wen, M.D.

Co-Author

This page shows the publications co-authored by Patrick Wen and Ayal Aizer.
Connection Strength

4.770
  1. Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro Oncol. 2022 Jun 28.
    View in: PubMed
    Score: 0.982
  2. Predictors of long-term survival among patients with brain metastases. Neuro Oncol. 2022 03 12; 24(3):494-496.
    View in: PubMed
    Score: 0.241
  3. Incidence and Predictors of Neurologic Death in Patients with Brain Metastases. World Neurosurg. 2022 Jun; 162:e401-e415.
    View in: PubMed
    Score: 0.241
  4. Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: A population- and institutional-level analysis. Neurooncol Pract. 2022 Apr; 9(2):114-122.
    View in: PubMed
    Score: 0.235
  5. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol. 2021 09 01; 23(9):1447-1456.
    View in: PubMed
    Score: 0.232
  6. Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. Neurooncol Pract. 2021 Oct; 8(5):569-580.
    View in: PubMed
    Score: 0.227
  7. Population-based estimates of survival among elderly patients with brain metastases. Neuro Oncol. 2021 04 12; 23(4):661-676.
    View in: PubMed
    Score: 0.226
  8. Seizures Among Patients with Brain Metastases: A Population- and Institutional-level Analysis. Neurology. 2021 Jan 05.
    View in: PubMed
    Score: 0.222
  9. Utility of claims data for delineation of intracranial treatment among patients with brain metastases. Neuro Oncol. 2020 10 14; 22(10):1547-1548.
    View in: PubMed
    Score: 0.218
  10. Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. Cureus. 2019 May 23; 11(5):e4726.
    View in: PubMed
    Score: 0.198
  11. Local control after brain-directed radiation in patients with cystic versus solid brain metastases. J Neurooncol. 2019 Apr; 142(2):355-363.
    View in: PubMed
    Score: 0.194
  12. Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiother Oncol. 2018 03; 126(3):511-518.
    View in: PubMed
    Score: 0.181
  13. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017 Oct 19; 19(11):1511-1521.
    View in: PubMed
    Score: 0.177
  14. Brain Metastases in Newly Diagnosed Breast Cancer: A Population-Based Study. JAMA Oncol. 2017 Aug 01; 3(8):1069-1077.
    View in: PubMed
    Score: 0.175
  15. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
    View in: PubMed
    Score: 0.153
  16. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
    View in: PubMed
    Score: 0.153
  17. Radiotherapy and death from cerebrovascular disease in patients with primary brain tumors. J Neurooncol. 2015 Sep; 124(2):291-7.
    View in: PubMed
    Score: 0.151
  18. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
    View in: PubMed
    Score: 0.140
  19. A molecularly integrated grade for meningioma. Neuro Oncol. 2022 05 04; 24(5):796-808.
    View in: PubMed
    Score: 0.061
  20. DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. J Neurooncol. 2022 May; 157(3):499-510.
    View in: PubMed
    Score: 0.060
  21. Highlights of the 2019 Society for Neuro-Oncology Inaugural Brain Metastases Conference: establishing a dedicated meeting to address an unmet need in the field. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa036.
    View in: PubMed
    Score: 0.052
  22. A low percentage of metastases in deep brain and temporal lobe structures. Neuro Oncol. 2019 05 06; 21(5):640-647.
    View in: PubMed
    Score: 0.049
  23. Radiographic prediction of meningioma grade by semantic and radiomic features. PLoS One. 2017; 12(11):e0187908.
    View in: PubMed
    Score: 0.045
  24. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. J Neurooncol. 2017 Dec; 135(3):581-591.
    View in: PubMed
    Score: 0.044
  25. Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma. Neuro Oncol. 2016 05; 18(5):649-55.
    View in: PubMed
    Score: 0.039
  26. Hypofractionated versus standard radiation therapy with or without temozolomide for older glioblastoma patients. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):384-9.
    View in: PubMed
    Score: 0.037
  27. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.